Retrospective analysis of coagulopathy in patients with severe renal insufficiency caused by tigecycline
- VernacularTitle:替加环素致严重肾功能不全患者凝血功能异常的回顾性分析
- Author:
Li SHEN
1
;
Wei FANG
1
;
Yao ZHANG
1
;
Yang PAN
1
;
Zewei ZHOU
1
Author Information
1. Dept. of Pharmacy，Three Gorges Hospital Affiliated to Chongqing University，Chongqing 404000，China
- Publication Type:Journal Article
- Keywords:
tigecycline;
coagulopathy;
renal insufficiency;
adverse reaction
- From:
China Pharmacy
2023;34(22):2766-2769
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the effects of tigecycline on coagulation function in patients with severe renal insufficiency， and to provide a reference for safe clinical drug use. METHODS Retrospective analysis was performed for the clinical data of patients with severe renal dysfunction complicated with infection receiving tigecycline admitted to nephrology department of our hospital from January 2021 to October 2022. The levels of prothrombin time （PT）， activated partial thromboplastin time （APTT）， international normalized ratio （INR）， platelet （PLT） and fibrinogen （FIB） were compared 3 days before medication， with 1-5， 6-10， 11-15 and 16-20 days after medication， 5 days after withdrawal and/or after symptomatic treatment. RESULTS Finally， 14 patients were included， and 9 patients developed coagulopathy， with an incidence of 64.29%. Compared with 3 days after medication， the levels of FIB at 6-10 and 11-15 days after medication， and PLT at 1-5 ， 6-10 and 11- 15 days after medication were decreased significantly， while the levels of PT at 1-5 and 6-10 days after medication， APTT at 1-5， 6-10 and 11-15 days after medication were significantly prolonged， and INR increased significantly at 1-5 and 6-10 days after medication （P＜0.05）. Compared with 3 days before medication， there were no statistically significant changes in FIB， PT， INR， APTT and PLT at 16-20 days after medication and 5 days after withdrawal and/or symptomatic treatment（P＞0.05）. CONCLUSIONS Patients with severe renal insufficiency should be cautious with tigecycline， which can lead to prolonged PT and APTT， increased INR， and decreased PLT and FIB. If medication time is over 14 days， dynamic monitoring of coagulation function indicators is recommended to reduce the risk of adverse reactions.
